Daily cost of antimicrobial therapy in patients with Intensive Care Unit-acquired, laboratory-confirmed bloodstream infection.

This study analysed daily antimicrobial costs of Intensive Care Unit (ICU)-acquired, laboratory-confirmed bloodstream infection (BSI) per patient admitted to the ICU of a university hospital, based on prospectively collected data over a 4-year period (2003-2006). Costs were calculated based on the price of the agent(s) initiated on the first day of appropriate treatment and according to: (i) focus of infection; (ii) pathogen; and (iii) antimicrobial agent. The study included 310 adult patients who developed 446 BSI episodes. Mean overall daily antimicrobial cost was euro114.25. Daily antimicrobial cost was most expensive for BSIs with unknown focus (euro137.70), followed by catheter-related (euro122.73), pulmonary (euro112.80), abdominal (euro98.00), wound (euro89.21), urinary (euro87.85) and other inciting focuses (euro81.59). Coagulase-negative staphylococci were the most prevalent pathogens isolated. Treatment of BSIs caused by Candida spp. was the most costly. The daily antimicrobial costs per infected patient with multidrug-resistant BSI was ca. 50% higher compared with those without (euro165.09 vs. euro82.67; P<0.001). Among the total of 852 prescriptions, beta-lactam antibiotics accounted for approximately one-third of the overall daily cost of antimicrobial agents. The antibiotic cost associated with ICU-acquired, laboratory-confirmed BSI is significant and should be reduced by implementing infection control measures and preventive strategies.

Outcome and changes over time in survival following severe burns from 1985 to 2004.

OBJECTIVE: To investigate outcome in severely burned patients over a 20-year period and to evaluate survival over time. DESIGN AND SETTING: Historical cohort in a six-bed burn unit of a 1060-bed university hospital. PATIENTS: 1385 patients admitted to the burn unit over a 20-year period. MEASUREMENTS AND RESULTS: Outcome was evaluated in relation to the presence of three major risk factors for death: age 60 years or over, total burned surface area 40% or more, and the presence of inhalation injury. Overall mortality was 7.1%. When zero, one, two, or three risk factors were present, mortality was respectively 0.5%, 9.9%, 48.0%, and 90.5%. Over the study period the average proportional total burned surface area decreased as did mortality. The survival benefit was significant among patient groups with one or two risk factors present. Multivariate regression analysis adjusting for risk factors for death confirmed that survival improved over time (odds ratio 0.73 per 5-year period). CONCLUSIONS: Global mortality following burns is low, and nearly all patients who die had at least one risk factor present. In the presence of three risk factors the prognosis following burns is particularly compromised. Taking into account that our patients over the past 20 years have been progressively less extensively burned and hence have a lesser at risk for death, survival following severe burns has continued to improve.